Pages that link to "Q45892140"
Jump to navigation
Jump to search
The following pages link to Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. (Q45892140):
Displaying 50 items.
- Epidemiology and clinical course of Crohn's disease: results from observational studies (Q22241217) (← links)
- Inflammatory bowel disease surgery in the biologic era (Q26745627) (← links)
- Current status of biosimilars in the treatment of inflammatory bowel diseases (Q26765350) (← links)
- How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease? (Q26777409) (← links)
- Current management of anal fistulas in Crohn's disease (Q26777667) (← links)
- Medical Therapy of Fibrostenotic Crohn's Disease (Q26777724) (← links)
- Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal (Q26801119) (← links)
- Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease (Q26827444) (← links)
- Optimising monitoring in the management of Crohn's disease: a physician's perspective (Q27007083) (← links)
- Use of the tumor necrosis factor-blockers for Crohn's disease (Q27030762) (← links)
- Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular View (Q27679553) (← links)
- THERAPIES FOR CROHN'S DISEASE: a clinical update (Q28070271) (← links)
- Ustekinumab for the treatment of Crohn's disease (Q30390909) (← links)
- Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study (Q31113830) (← links)
- Biological treatment of Crohn's disease (Q33354991) (← links)
- Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe--a Hungarian nationwide observational study (Q33501390) (← links)
- Does long-term efficacy differ between infliximab and adalimumab after 1 year of continuous administration?: A STROBE-compliant retrospective cohort study (Q33606172) (← links)
- Discontinuation of Scheduled Infliximab in Crohn's Patients With Clinical Remission: A Retrospective Single-Center Study (Q33625252) (← links)
- Diagnosis and management of intestinal Behçet's disease. (Q33681591) (← links)
- Infliximab dosing patterns in a sample of patients with Crohn's disease: results from a medical chart review (Q33724975) (← links)
- Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease (Q33819478) (← links)
- Medical management of Crohn's disease. (Q34046139) (← links)
- Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease (Q34127277) (← links)
- The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? (Q34147687) (← links)
- Current status of thiopurine analogues in the treatment in Crohn's disease. (Q34235370) (← links)
- Mucosal healing did not predict sustained clinical remission in patients with IBD after discontinuation of one-year infliximab therapy (Q34374449) (← links)
- Medical therapy of stricturing Crohn's disease: what the gut can learn from other organs - a systematic review (Q34504710) (← links)
- A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes (Q34837921) (← links)
- Infliximab therapy for moderately severe Crohn’s disease and ulcerative colitis: a retrospective comparison over 6 years (Q35026410) (← links)
- Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease (Q35134059) (← links)
- Current treatment of ulcerative colitis (Q35171533) (← links)
- Risk of postoperative recurrence and postoperative management of Crohn's disease (Q35171537) (← links)
- Infliximab preferentially induces clinical remission and mucosal healing in short course Crohn's disease with luminal lesions through balancing abnormal immune response in gut mucosa (Q35250578) (← links)
- Infliximab to treat Crohn's disease: an update. (Q35304737) (← links)
- Inhibition of 4-1BBL-regulated TLR response in macrophages ameliorates endotoxin-induced sepsis in mice (Q35565652) (← links)
- Combination therapy for the treatment of Crohn's disease (Q35714202) (← links)
- Specialized enteral nutrition therapy in Crohn's disease patients on maintenance infliximab therapy: a meta-analysis (Q35780904) (← links)
- Effect of a continuous measure of adherence with infliximab maintenance treatment on inpatient outcomes in Crohn's disease (Q36048409) (← links)
- Crucial steps in the natural history of inflammatory bowel disease. (Q36144457) (← links)
- Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease (Q36330198) (← links)
- Efficacy of Adalimumab in Korean Patients with Crohn's Disease (Q36658432) (← links)
- Effectiveness of concomitant enteral nutrition therapy and infliximab for maintenance treatment of Crohn's disease in adults (Q36865926) (← links)
- Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis (Q37051515) (← links)
- Challenges in IBD research: update on progress and prioritization of the CCFA's research agenda (Q37087227) (← links)
- Early surgery in Crohn's disease a benefit in selected cases. (Q37089435) (← links)
- Non-adherence to Anti-TNF Therapy is Associated with Illness Perceptions and Clinical Outcomes in Outpatients with Inflammatory Bowel Disease: Results from a Prospective Multicentre Study (Q37118400) (← links)
- JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines (Q37148745) (← links)
- Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort (Q37252833) (← links)
- Is early limited surgery associated with a more benign disease course in Crohn's disease? (Q37334129) (← links)
- A Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn's Disease Treated with Adalimumab or Infliximab (Q37373219) (← links)